Medical Bionanotechnology, Faculty of Allied Health Sciences, Chettinad Hospital & Research Institute (CHRI), Chettinad Academy of Research and Education (CARE), Chennai, India.
Department of Pharmacology, Chettinad Hospital & Research Institute (CHRI), Chettinad Academy of Research and Education (CARE), Chennai, India.
Ann Med. 2024 Dec;56(1):2352022. doi: 10.1080/07853890.2024.2352022. Epub 2024 May 16.
Uric acid (UA) levels in blood serum have been associated with hypertension, indicating a potential causal relationship between high serum UA levels and the progression of hypertension. Therefore, the reduction of serum UA level is considered a potential strategy for lowering and mitigating blood pressure. If an individual is at risk of developing or already manifesting elevated blood pressure, this intervention could be an integral part of a comprehensive treatment plan. By addressing hyperuricaemia, practitioners may subsidize the optimization of blood pressure regulation, which illustrates the importance of addressing UA levels as a valuable strategy within the broader context of hypertension management. In this analysis, we outlined the operational principles of effective xanthine oxidase inhibitors for the treatment of hyperuricaemia and hypertension, along with an exploration of the contribution of nanotechnology to this field.
血清尿酸(UA)水平与高血压有关,这表明高血清 UA 水平与高血压的进展之间存在潜在的因果关系。因此,降低血清 UA 水平被认为是降低和缓解血压的一种潜在策略。如果一个人有发生或已经表现出高血压的风险,这种干预可能是全面治疗计划的一个组成部分。通过治疗高尿酸血症,医生可以辅助优化血压调节,这说明了在高血压管理的更广泛背景下,将 UA 水平作为一种有价值的策略进行处理的重要性。在这项分析中,我们概述了有效黄嘌呤氧化酶抑制剂治疗高尿酸血症和高血压的作用原理,并探讨了纳米技术在这一领域的贡献。